Navigation Links
New influenza vaccine takes weeks to mass produce

Using cell-based methods researchers have developed a commercially viable method for mass producing effective vaccines against potential pandemic influenza strains in weeks instead of the months required for traditional egg-based vaccines. They report their results today at the 2006 ASM Biodefense Research

The next flu pandemic could happen any time," says Keyang Wang, a scientist at Protein Sciences Corporation (PSC) and a researcher on the study. "The most effective method to control such an outbreak is the widespread use of a vaccine, preferably in a pro-active manner, so that the immune system is primed prior to actual virus exposure. The traditional egg-based method requires 3 to 6 months to develop the vaccine. With our cell-based method, as soon as the pandemic strain is identified, a matched vaccine can be massively produced within 4 weeks."

The vaccine strategy pursued by Protein Sciences, known commercially as FluBlok, uses a purified protein from the surface of the virus called hemagglutinin (the H part of a virus' designation, like H5N1 for the current avian influenza) to elicit an immune response to a specific strain of influenza. The protein is produced by first extracting the genes responsible for the production of hemagglutinin from the influenza virus and inserting them into a baculovirus. Specific host cells are then infected with the baculovirus and produce recombinant hemagglutinin (rHA). Phase II clinical trials show that rHA-based vaccines produced using this system are safe, elicit immunity equal to or greater than egg-based vaccines, and are 100% effective in the prevention of cell culture confirmed influenza.

Wang and his colleagues report the successful production of rHA from 4 strains of influenza that scientists believe to be likely the cause of the next pandemic (H5, H7, H9, and H2) at a level where manufacturing costs are expected to be equal to or less than that of traditional egg-based vaccines.

"It has been suggested that the next pandemic strain may be derived from H5, H7, H9 or H2 influenza viruses. The preparation of the recombinant baculoviruses for the production of these antigens and the successful purifications gives us a great advantage in fighting against a potential influenza pandemic, if it derived from any of these strains," says Wang. "Starting from a stocked recombinant baculovirus bank, a closely matched vaccine can be massively produced within 2 weeks."

PSC has recently signed a Letter of Intent which will support commercial scale manufacturing with the capacity to produce 6 Million doses of monovalent pandemic vaccine per week.


'"/>

Source:American Society for Microbiology


Related biology news :

1. Computers to be used to find blueprint for new influenza drug
2. Less virulent strains of avian influenza can infect humans
3. Drug resistant avian influenza viruses more common in Southeast Asia than North America
4. New vaccine platform may fight infections with causes from influenza to bioterrorism
5. First big influenza genome study reveals flu evolution
6. Web model of influenza-host lifecycles will aid scientists in creating anti-viral drugs
7. Study outlines genetic differences between potential pandemic influenza strains
8. Avian influenza virus in mammals spreads beyond the site of infection to other organ systems
9. How can we protect patients with weakened immune systems from influenza?
10. Mouse study reveals new clues about virulence of 1918 influenza virus
11. Molecular anatomy of influenza virus detailed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2017)... MONICA, Calif. , April 13, 2017 ... New York will feature emerging and evolving ... Summits. Both Innovation Summits will run alongside the expo ... of speaker sessions, panels and demonstrations focused on trending ... coast,s largest advanced design and manufacturing event will take ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences , ... life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer ... “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
(Date:10/9/2017)... , ... October 09, 2017 , ... At its national ... Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been ... a member of the winning team for the 2015 Breakthrough Prize in Fundamental physics ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography ... generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase ...
Breaking Biology Technology: